Literature DB >> 12067953

Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.

M T Meinardi1, W T A Van Der Graaf, J A Gietema, M P Van Den Berg, D T Sleijfer, E G E De Vries, J Haaksma, F Boomsma, D J Van Veldhuisen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12067953      PMCID： PMC1767181          DOI： 10.1136/heart.88.1.81

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  5 in total

Review 1.  A practical guide to assessment of ventricular diastolic function using Doppler echocardiography.

Authors:  G I Cohen; J F Pietrolungo; J D Thomas; A L Klein
Journal:  J Am Coll Cardiol       Date:  1996-06       Impact factor: 24.094

2.  Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables.

Authors:  G Tjeerdsma; M T Meinardi; W T van Der Graaf; M P van Den Berg; N H Mulder; H J Crijns; E G de Vries; D J van Veldhuisen
Journal:  Heart       Date:  1999-04       Impact factor: 5.994

3.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

Review 4.  Anthracycline-induced cardiotoxicity.

Authors:  K Shan; A M Lincoff; J B Young
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

5.  Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.

Authors:  M Ryberg; D Nielsen; T Skovsgaard; J Hansen; B V Jensen; P Dombernowsky
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544
  5 in total
  7 in total

1.  Three versus six months of exercise training in breast cancer survivors.

Authors:  Lisa K Sprod; City C Hsieh; Reid Hayward; Carole M Schneider
Journal:  Breast Cancer Res Treat       Date:  2010-05-05       Impact factor: 4.872

2.  Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin.

Authors:  Angel Qin; Cheryl L Thompson; Paula Silverman
Journal:  J Cancer Surviv       Date:  2014-10-24       Impact factor: 4.442

Review 3.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

Authors:  Elvira C van Dalen; Erna Mc Michiels; Huib N Caron; Leontien Cm Kremer
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

4.  Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study.

Authors:  Szu-Erh Chan; Hung-Wen Lai; Chin-Cheng Su; Shou-Jen Kuo; Su-Yu Chien; Hui-Yi Lin; Dar-Ren Chen
Journal:  Evid Based Complement Alternat Med       Date:  2011-05-24       Impact factor: 2.629

5.  Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.

Authors:  S Romano; S Fratini; E Ricevuto; V Procaccini; G Stifano; M Mancini; M Di Mauro; C Ficorella; M Penco
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

6.  Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.

Authors:  Sherry-Ann Brown; Svetlana Zaharova; Peter Mason; Jonathan Thompson; Bicky Thapa; David Ishizawar; Erin Wilkes; Gulrayz Ahmed; Jason Rubenstein; Joyce Sanchez; David Joyce; Balaraman Kalyanaraman; Michael Widlansky
Journal:  Front Cardiovasc Med       Date:  2020-12-04

Review 7.  Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.

Authors:  Elvira C van Dalen; Helena J H van der Pal; Leontien C M Kremer
Journal:  Cochrane Database Syst Rev       Date:  2016-03-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.